Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 4/20 | 0.72 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13459214 | 1.00 | APLNR (0.72) | APLNREPHX1HIF1AALDH1A1CYP1A2 | |
| SCHEMBL16307180 | 1.00 | APLNR (0.72) | APLNREPHX1HIF1AALDH1A1CYP1A2 | |
| SCHEMBL15492395 | 1.00 | APLNR (0.72) | APLNREPHX1HIF1AALDH1A1CYP1A2 | |
| SCHEMBL330620 | 1.00 | — | — | |
| SCHEMBL1457267 | 1.00 | APLNR (0.72) | APLNREPHX1HIF1AALDH1A1CYP1A2 | |
| SCHEMBL5970910 | 1.00 | APLNR (0.72) | APLNREPHX1HIF1AALDH1A1CYP1A2 | |
| SCHEMBL710256 | 0.97 | — | — | |
| SCHEMBL6081194 | 0.91 | — | — | |
| SCHEMBL13917961 | 0.85 | APLNR (0.67) | APLNREPHX1HIF1AALDH1A1 | |
| SCHEMBL3903198 | 0.84 | APLNR (1.00) | APLNREPHX1HIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888596-B1 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-8772307-B2 | Substituted spiro compounds and their use for producing pain-relief medicaments | GRUENENTHAL GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| EP-2292625-B1 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2013-12-25 | — | — | EP | disclosed |
| EP-2292625-A1 | Substituted spiro compounds and their use for producing pain-relief medicaments | Grünenthal GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
| US-20080269271-A1 | Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders | GRUENENTHAL GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080200404-A1 | Novel Antimalarial 9A-Carbamoyl-Aminoalkyl and 9A-Thiocarbamoyl-Aminoalkyl Azalides | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (HR) | 2008-08-21 | — | — | US | disclosed |
| US-20080200404-A1 | Novel Antimalarial 9A-Carbamoyl-Aminoalkyl and 9A-Thiocarbamoyl-Aminoalkyl Azalides | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (HR) | 2008-08-21 | — | — | US | disclosed |
| EP-1893620-A2 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF DRUGS | Grünenthal GmbH (DE) | 2008-03-05 | — | — | EP | disclosed |
| EP-1888596-A1 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS | Grünenthal GmbH (DE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006122769-A2 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF DRUGS | Grünenthal GmbH (DE) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006122770-A1 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS | Grünenthal GmbH (DE) | 2006-11-23 | — | — | WO | disclosed |
| US-20050042674-A9 | Common ligand mimics: thiazolidinediones and rhodanines | TRIAD THERAPEUTICS, INC. | 2005-02-24 | — | — | US | disclosed |
| US-20050019825-A9 | Common ligand mimics: pseudothiohydantoins | TRIAD THERAPEUTICS, INC. | 2005-01-27 | — | — | US | disclosed |
| US-6689777-B2 | DEPOLYMERIZING HEMOZOIN USING 2-IMINO-NAPHTHO(1,2-D)THIAZOL-5-OL DERIVATIVES | KENNETH S. WARREN INSTITUTE | 2004-02-10 | — | — | US | disclosed |
| US-20030186993-A1 | Anti-malarial compounds, compositions and methods | KENNETH S. WARREN INSTITUTE | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050019825-A9 | Common ligand mimics: pseudothiohydantoins | FGFR3, BID, FLT3 | APLNR 66/4885EPHX1 1814/4885HIF1A 2054/4885 |
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | REN, PKD1, NR3C2 | APLNR 3737/4885EPHX1 1142/4885HIF1A 2059/4885 |
| US-20030186993-A1 | Anti-malarial compounds, compositions and methods | TYR, CRYZ, RHOT2 | APLNR 4581/4885EPHX1 2950/4885HIF1A 1992/4885 |
| US-20080269271-A1 | Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders | INA, SCN1A, SI | APLNR 1472/4885EPHX1 3722/4885HIF1A 963/4885 |
| US-20050042674-A9 | Common ligand mimics: thiazolidinediones and rhodanines | GPR65, NR2E3, FGFR3 | APLNR 272/4885EPHX1 3074/4885HIF1A 2953/4885 |
| US-20080200404-A1 | Novel Antimalarial 9A-Carbamoyl-Aminoalkyl and 9A-Thiocarbamoyl-Aminoalkyl Azalides | DCTD, DHODH, DHRS9 | APLNR 660/4885EPHX1 1947/4885HIF1A 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.